Symposium 9: The Growing Problem of Dosing the Obese Patient: What the Product Information Doesn’t Tell You |
Wednesday September 16, 1200-1300 (UTC)
Introduction and Dosing the Obese Elderly Patient
Dario Cattaneo, ASST Fatebenefratelli Sacco University Hospital, Italy
Learning Objectives: At the end of this session participants will be able to:
- Discuss how obesity represents an important source of drugs PK variability.
- Consider the patient’s body composition when calculating doses.
- Explain the advantages and disadvantages of body size metrics of obese patients.
- Consider aging as an additional contributor of drug variability in obese patients.
Anti-Infective Dosing in the Obese Child
Catherijne A.J. Knibbe, St Antonius Hospital Nieuwegein, Leiden University, Netherlands
Learning Objectives: At the end of this session participants will be able to:
- Define pediatric overweight and obesity.
- Explain the differences in influence of obesity on pharmacokinetics between drugs.
- Discuss the differences in obesity-related influence on pharmacokinetics between obese adults and obese children.
- Reflect on the use of total bodyweight or other weight measures for dosing in obese children.
Dosing the Patient with Obesity; Changes with Weight Reduction
Anders Åsberg, Oslo University Hospital–Rikshospitalet, Norway
Learning Objectives: At the end of this session participants will be able to:
- Explain differences in CYP activities over a wide range of bodyweights.
- Discuss the effect of weight reduction on CYP activities.
Dario Cattaneo, ASST Fatebenefratelli Sacco University Hospital, Italy
Learning Objectives: At the end of this session participants will be able to:
- Discuss how obesity represents an important source of drugs PK variability.
- Consider the patient’s body composition when calculating doses.
- Explain the advantages and disadvantages of body size metrics of obese patients.
- Consider aging as an additional contributor of drug variability in obese patients.
Anti-Infective Dosing in the Obese Child
Catherijne A.J. Knibbe, St Antonius Hospital Nieuwegein, Leiden University, Netherlands
Learning Objectives: At the end of this session participants will be able to:
- Define pediatric overweight and obesity.
- Explain the differences in influence of obesity on pharmacokinetics between drugs.
- Discuss the differences in obesity-related influence on pharmacokinetics between obese adults and obese children.
- Reflect on the use of total bodyweight or other weight measures for dosing in obese children.
Dosing the Patient with Obesity; Changes with Weight Reduction
Anders Åsberg, Oslo University Hospital–Rikshospitalet, Norway
Learning Objectives: At the end of this session participants will be able to:
- Explain differences in CYP activities over a wide range of bodyweights.
- Discuss the effect of weight reduction on CYP activities.
The Obese Patient in the Intensive Care Unit
Debbie Marriott, St Vincent’s Hospital, Australia
Learning Objectives: At the end of this session participants will be able to:
- Describe the pathophysiological changes associated with critical illness.
- Determine the impact of obesity on these changes.
- Discuss the literature concerning antimicrobial dosing in the obese critically ill patient.
- Explain the role of antimicrobial therapeutic drug monitoring in this clinical setting.
Debbie Marriott, St Vincent’s Hospital, Australia
Learning Objectives: At the end of this session participants will be able to:
- Describe the pathophysiological changes associated with critical illness.
- Determine the impact of obesity on these changes.
- Discuss the literature concerning antimicrobial dosing in the obese critically ill patient.
- Explain the role of antimicrobial therapeutic drug monitoring in this clinical setting.